APPIS examines capability building gaps of Patient Organizations
The Asia Pacific Patient innovation Summit has published a whitepaper, which aims to serve as a blueprint to help patient organizations improve their approach to sustainable funding, digitalization, and multi-stakeholder partnerships.
Dr Ratna Devi, Board Chair of the International Alliance of Patients’ Organisations and APPIS 2021 Steering Committee Chair commented, “This is an important initiative for patient organizations in the region. I hope that the whitepaper will provide a greater understanding and recognition of the seminal role of patient organizations. We want to start conversations that will eventually lead to changes in practice and policy to give patients a bigger voice at the table in healthcare discussions.”
“We aim to bring our Commitment to Patients and Caregivers to life in this part of the world by strengthening our partnerships with the patient community. Only by working together can we extend and improve people’s lives by continuing to improve the standards of healthcare and elevating the patient experience”, said Ruth Kuguru, Head of Patient Engagement and Communications for Asia Pacific, Middle East and Africa of Novartis and member of the APPIS 2021 Steering Committee.
APPIS: An initiative led by patient organizations for patient organizations
APPIS is a unique collaborative partnership between Novartis and the patient community that aims to address the evolving capability needs of patient organizations and to drive changes in healthcare systems in Asia Pacific and beyond. Held in March 2021, the inaugural region-wide Summit saw over 880 participants throughout the three-day event, representing more than 300 patient organizations across 36 countries and territories, including Australia, India, mainland China, Japan, South Korea, Taiwan, Thailand, Philippines, UAE, Saudi Arabia, South Africa, Egypt, and so on.
Funded by Novartis and led by patient organizations, the APPIS Initiative is continuing to engage the patient community via ongoing capability modules offered by APPIS partners – Rare Cancers Australia (RCA) and the European Patients’ Academy on Therapeutic Innovation (EUPATI).